Pesquisar
Silence Therapeutics PLC
SLNAdicionar à lista de desejos
10.390USD
-0.110-1.05%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
490.76MValor de mercado
PerdaP/L TTM
Mais detalhes de Silence Therapeutics PLC Empresa
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Informações de Silence Therapeutics PLC
Código da empresaSLN
Nome da EmpresaSilence Therapeutics PLC
Data de listagemJan 05, 2010
CEOTooman (Craig A)
Número de funcionários116
Tipo de títulosDepository Receipt
Fim do ano fiscalJan 05
Endereço72 Hammersmith Road
CidadeLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalW14 8TH
Telefone442034576900
Sitehttps://www.silence-therapeutics.com/
Código da empresaSLN
Data de listagemJan 05, 2010
CEOTooman (Craig A)
Executivos da empresa Silence Therapeutics PLC
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Silence Therapeutics PLC?
Os cinco principais acionistas de Silence Therapeutics PLC são: Mr. David Jakob (Dave) Lemus, CPA
Quantas instituições possuem ações da Silence Therapeutics PLC (SLN)?
Em 2026Q1, 147 instituições possuíam ações da Silence Therapeutics PLC, com valor de mercado aproximado de 19.17M, representando 40.59% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -12508865.00.